These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
410 related items for PubMed ID: 1406793
1. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. N Engl J Med; 1992 Oct 22; 327(17):1209-15. PubMed ID: 1406793 [Abstract] [Full Text] [Related]
2. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Foon KA, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Bernstein Z, Pincus S, Köhler H, Seon BK, Tahaoglu E. Clin Cancer Res; 1995 Nov 22; 1(11):1285-94. PubMed ID: 9815923 [Abstract] [Full Text] [Related]
8. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R. N Engl J Med; 1985 Jun 27; 312(26):1658-65. PubMed ID: 3923352 [Abstract] [Full Text] [Related]
13. Towards an idiotype vaccine against mammary tumors. Induction of an immune response to breast cancer-associated antigens by anti-idiotypic antibodies. Smorodinsky NI, Ghendler Y, Bakimer R, Chaitchuk S, Keydar I, Shoenfeld Y. Eur J Immunol; 1988 Nov 27; 18(11):1713-8. PubMed ID: 2849550 [Abstract] [Full Text] [Related]
14. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Rinaldi M, Ria F, Parrella P, Signori E, Serra A, Ciafrè SA, Vespignani I, Lazzari M, Farace MG, Saglio G, Fazio VM. Cancer Res; 2001 Feb 15; 61(4):1555-62. PubMed ID: 11245465 [Abstract] [Full Text] [Related]
15. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. Syrengelas AD, Levy R. J Immunol; 1999 Apr 15; 162(8):4790-5. PubMed ID: 10202021 [Abstract] [Full Text] [Related]
16. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R. J Immunol; 1988 Jul 01; 141(1):333-9. PubMed ID: 3132505 [Abstract] [Full Text] [Related]
18. Human anti-idiotypic T lymphocyte clones are activated by autologous anti-rabies virus antibodies presented in association with HLA-DQ molecules. UytdeHaag F, Claassen I, Bunschoten H, Loggen H, Ottenhoff T, Teeuwsen V, Osterhaus A. J Mol Cell Immunol; 1987 Jul 01; 3(3):145-55. PubMed ID: 2908179 [Abstract] [Full Text] [Related]
19. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014 [Abstract] [Full Text] [Related]
20. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Tao MH, Levy R. Nature; 1993 Apr 22; 362(6422):755-8. PubMed ID: 8469286 [Abstract] [Full Text] [Related] Page: [Next] [New Search]